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Deletions on chromosomes 5 and 7 are frequently seen in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
It is assumed that these deletions indicate loss of tumor suppressor genes on these chromosomes and until these tumor
suppressor genes are identified, the functional consequences of these deletions and the molecular basis of these myeloid
disorders cannot be completely understood. We evaluated loss of heterozygosity (LOH) in 44 patients (18 MDS and 26 AML,
diagnosed according to WHO classification criteria) at diagnosis, using a four-microsatellite marker panel: an intragenic marker
on the 7th intron of gene IRF-1 of the 5q31.1 region and three markers located inside the 7q31.1 region and correlated the LOH
with karyotype abnormalities. The microsatellites chosen corresponded to chromosome regions frequently deleted in MDS/
AML. The samples with Q (peak area) less than or equal to 0.50 were indicative of LOH. The percent of informative samples (i.e.,
heterozygous) for the intragenic microsatellite in gene IRF-1 and in loci D7S486, D7S515 and D7S522 were 66.6, 73.7, 75.5, and
48.8%, respectively. Cytogenetic abnormalities by G-banding were found in 36% (16/44) of the patients (2 of 18 MDS and 14 of
26 AML patients). We found a significantly positive association of the occurrence of LOH with abnormal karyotype (P < 0.05; chi-
square test) and there were cases with LOH but the karyotype was normal (by G-banding). These data indicate that LOH in
different microsatellite markers is possibly an event previous to chromosomal abnormalities in these myeloid neoplasias.
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Loss of heterozygosity (LOH) describes the homozy-
gous state of a distinct chromosomal region and points to
the presence of closely located inactivated tumor suppres-
sor gene (TSG) that may be involved in the malignant
transformation (1,2). Loss of heterozygosity in tumor cells
has been analyzed using microsatellite markers (2).
Cytogenetic abnormalities are important to identify
malignant cells and to indicate prognosis in myeloid malig-
nancies (3). Translocations, duplications, deletions, inser-
tions, and inversions involve the repositioning, addition or
omission of millions of nucleotides and are associated with
genomic instability in cancer cells.
Myelodysplastic syndrome (MDS) and acute myeloid
leukemia (AML) are myeloid malignant disorders of he-
matopoietic stem cells characterized by numerous cytoge-
netic abnormalities. Alterations on chromosome 5, which
include interstitial deletions of the long arm or complete
loss of the entire chromosome (monosomy 5), are fre-
quently observed in MDS and AML patients (3). Deletion of
chromosome 7q is also common in MDS and AML. Loss of
whole chromosome 7 or deletion of the long arm are
detected in up to 20% of patients with MDS or AML and the
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highest frequency is noted in MDS and AML arising after
cytotoxic therapy (3). It is assumed that these deletions
indicate loss of possible TSG in these chromosomes and
until these TSG are identified, the functional consequences
of these deletions and the molecular basis of these my-
eloid disorders cannot be completely understood.
Chromosome abnormalities are important markers of
genetic instability but are considered to be late events
during MDS transformation and AML evolution. The ques-
tion is what are the initial steps in MDS and AML related to
these abnormalities? Could LOH be a sign of future alter-
ations in these cases?
The aim of this report is to evaluate LOH in MDS and
AML patients using a four-microsatellite marker panel: an
intragenic marker on the 7th intron of gene interferon
regulatory factor 1 (IRF-1 ) of the 5q31.1 region and three
markers located inside the 7q31.1 region and to correlate
the LOH with karyotype abnormalities.
Karyotype analysis was performed according to stand-
ard techniques (4). When possible, 20 G-banded meta-
phases were analyzed and classified according to the
International System for Human Cytogenetic Nomencla-
ture (5). Favorable karyotype in MDS was considered to be
del(20q), -Y, normal and del(5q) isolated; unfavorable
were complex karyotype (at least three abnormalities in
metaphase) and abnormalities of chromosome 7 (6); inter-
mediate were those not classified as favorable and unfa-
vorable. Favorable karyotype in AML was: inv(16)/t(16;16),
t(15;17) and t(8;21); intermediate was normal, +8, +6, -Y
and del(12p), while unfavorable were alterations of chro-
mosomes 3, 9, 11, 20, 21, del(5q), del(7q), -5, -7 and
complex karyotype (7).
Paired samples of bone marrow and buccal smears
were obtained, after informed consent, from 44 patients
(18 MDS and 26 AML) at diagnosis. This study was ap-
proved by the Institutional Review Ethics Committee. The
diagnoses of AML and MDS were made according to the
World Health Organization (Table 1) (8).
Buccal smear collection was carried out with sterile
cytology brushes and served as normal controls. Patients
were instructed to brush the inside of both sides of the
cheek for 30 s, and the brush was kept in a sterile saline
solution for extraction. Genomic DNA was extracted from
buccal smears by the Puregene DNA isolation kit (Gentra
Systems, USA) according to manufacturer recommenda-
tions.
Bone marrow samples were obtained for cytogenetic
analysis and for DNA extraction by standard procedures
(4). Bone marrow DNA was extracted by conventional cell
lysis and proteinase K method. DNA was purified by phe-
nol-chloroform extraction and precipitated with sodium
acetate and ethanol (9). The concentration and quality of
DNA were measured by the GeneQuant PRO RNA/DNA
calculator (GE Healthcare, USA).
PCR was performed on 25 ng DNA from bone marrow
aspirates and buccal smears, in a 25 µL containing 1X
buffer (20 mM Tris-HCl, pH 8.4, 50 mM KCl), 2 mM MgCl2,
200 µM of each dNTP, 10 pmol of each primer, and the
forward primer was 5’ end fluorescently labeled (FAM),
0.625 U (0.12 µL) AmpliTaq Gold DNA polymerase (PE
Applied Biosystems, USA) (9).
Amplification was performed in a Perkin Elmer 9700
Thermal Controller (PE Applied Biosystems) after an initial
denaturation at 94°C for 12 min. Twenty-five cycles were
performed using the following temperature and time pro-
file: denaturation at 94°C for 30 s, annealing at 55°C for 30
s, extension at 70°C for 30 s, and a final extension of 72°C
for 25 min to minimize stutter bands. The PCR products
were analyzed on a 6% polyacrylamide gel in 1X Tris-
borate-EDTA buffer in the 377 automated DNA sequencer
(PE Applied Biosystems). One microliter of each PCR
product was combined with 4 µL formamide, 0.5 µL blue
dextran, and 0.5 µL of a fluorescent size marker (GS 500
ROX; PE Applied Biosystems). The mixture samples were
heated to 90°C for 5 min and then cooled on ice until ready
to load.
The electrophoresis conditions were 3000 W and 51°C.
PCR products were quantitatively detected by fragmenta-
tion analysis using ABI GeneScan and ABI Genotyper
software (PE Applied Biosystems).
Cytogenetic abnormalities by G-banding were detected
in 36% (16/44) of the patients, specifically 2 of 18 MDS and
14 of 26 AML patients (Table 1).
The criteria selected for detecting allele loss were
described by Cawkwell et al. (10). The samples with Q
(peak area) less than or equal to 0.50 indicated LOH. The
percent of informative samples (i.e., heterozygous) for the
intragenic microsatellite in gene IRF-1 and in loci D7S486,
D7S515 and D7S522 were 66.6, 73.7, 75.5, and 48.8%,
respectively. The results of microsatellite analysis are
summarized in Table 2.
Allelic loss occurred in 2 of 29 (6%) informative cases
for IRF-1. One patient (case 21) was an AML with prior
MDS and the other (case 43) was an AML secondary to
therapy, both patients had an unfavorable karyotype ab-
normality.
LOH was detected for one or more markers in 5 of 44
(11%) patients. Cases 19 and 31 presented LOH for the 3
markers (D7S486, D7S515 and D7S522). Case 21 showed
LOH for markers D7S486 and D7S515 and cases 5 and 23
presented LOH for marker D7S515. Among the 2 patients
who presented deletion 5q (cases 15 and 21), only case 21
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Table 1. Classification of patients in the present study according to WHO criteria (8) and results of karyotyping and microsatellite
analyses.
Patient No. WHO classification Cytogenetics LOH
1 Refractory cytopenia with multilineage dysplasia (RCMD) Without metaphases
2 Refractory cytopenia with multilineage dysplasia (RCMD) 46,XX[20]
3 Refractory anemia with excess blasts-1 (RAEB-1) 46,XY[20]
4 Refractory anemia with ringed sideroblasts (RARS) 46,XY[20]
5 Refractory cytopenia with multilineage dysplasia (RCMD) 46,XX[20] D7S515
6 Refractory anemia with excess blasts-2 (RAEB-2) 46,XY[20]
7 Refractory anemia with ringed sideroblasts (RARS) 46,XX[20]
8 Refractory anemia (RA) Without metaphases
9 Refractory anemia (RA) 46,XY[20]
10 Refractory anemia with ringed sideroblasts (RARS) Without metaphases
11 Refractory anemia (RA) 46,XY[15]
12 Refractory anemia (RA) Without metaphases
13 Refractory cytopenia with multilineage dysplasia (RCMD) 46,XY[20]
14 Refractory anemia with ringed sideroblasts (RARS) Without metaphases
15 Refractory anemia with excess blasts-2 (RAEB-2) 46,XX,del(5)(q31)[15]
16 Refractory anemia with excess blasts-2 (RAEB-2) Condensed metaphases
17 Refractory cytopenia with multilineage dysplasia (RCMD) 46,XX[20]
18 Refractory anemia with excess blasts-1 (RAEB-1) 47,XY,+3[4]/46,XY[12]
19 AML with multilineage dysplasia with prior MDS 45,XY,-7[16]/46,XY[4] D7S486, 515, 522
20 AML with multilineage dysplasia with prior MDS 46,XY[15]
21 AML with multilineage dysplasia with prior MDS 47,XX,+8[1]/47,XX,del(5)(q13q33), IRF-1, D7S486, 515
del(7)(q22),+8[2]/49,XX,del
(7)(q22),+8,+11,+18[1]
22 AML with multilineage dysplasia with prior MDS 46,XX[20]
23 AML with multilineage dysplasia without prior MDS Without metaphases D7S515
24 AML with multilineage dysplasia without prior MDS 46,XX[20]
25 AML with multilineage dysplasia with prior MDS 46,XX,inc[9]
26 AML with multilineage dysplasia with prior MDS 46,XY[20]
27 AML with multilineage dysplasia with prior MDS 48,XX,+8,+9[10]
28 AML with multilineage dysplasia with prior MDS 48,XY,+14,+22[14]/46,XY[1]
39 AML not otherwise categorized/myelomonocytic 46,XY[8]
30 AML not otherwise categorized/monocytic 46,XY,t(1;2)(p31;q34)[20]
31 AML not otherwise categorized/AML without maturation 47,XY,+8[16]/46,XY[4] D7S486, 515, 522
32 AML not otherwise categorized/AML with maturation 46,XY[20]
33 AML with recurrent cytogenetic translocations/AML with 46,XY,t(8;21)(q22;q22)[15]
t(8;21)(q22;q22)
34 AML with recurrent cytogenetic translocations/AML with 46,XY,t(8;21)(q22;q22)[20]
t(8;21)(q22;q22)
35 AML with recurrent cytogenetic translocations/AML with 46,XX,t(15;17)(q22;q11)[20]
t(15;17)(q22;q12)
36 AML not otherwise categorized/AML with maturation 46,XX[20]
37 AML with recurrent cytogenetic translocations/ AML with 46,XX,t(15;17)(q22;q12)[20]
t(15;17)(q22;q12)
38 AML not otherwise categorized/AML without maturation 47,XX,del(7)(q31),+8[3]/46,XX[8]
39 AML not otherwise categorized/AML with maturation 46,XY[13]
40 AML not otherwise categorized/AML with maturation Without metaphases
41 AML not otherwise categorized/megakaryocytic 46,XX,add(21)(q22)[15]
42 AML not otherwise categorized/myelomonocytic Without metaphases
43 AML therapy related 53-56,XX,+1,+8,+9,+10,i?(11) IRF-1
(q13),+14,+15,+16,+17,+18,+19,
~6dmin
44 AML with recurrent cytogenetic translocations/AML with 46,XY,t(15;17)(q22;q12)[20]
t(15;17)(q22;q12)
WHO = World Health Organization; MDS = myelodysplastic syndrome; AML = acute myeloid leukemia; LOH = loss of heterozygosity.
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Table 2. Analysis of loss of heterozygosity (LOH) of the IRF-1
gene and the markers at 7q.
Patient No. IRF-1 Markers at 7q
D7S486 D7S515 D7S522
1 Homoz. 1.0 Homoz. Homoz.
2 0.98 0.92 1.0 Homoz.
3 0.91 0.91 0.83 1.0
4 1.0 Homoz. 1.0 1.0
5 0.94 0.78 0.23 Homoz.
6 1.0 0.91 0.83 Homoz.
7 Homoz. Homoz. Homoz. Homoz.
8 0.98 1.0 0.91 1.0
9 0.96 0.91 0.91 Homoz.
10 1.0 1.0 Homoz. Homoz.
11 Homoz. Homoz. 0.91 0.83
12 0.97 0.77 0.91 Homoz.
13 0.96 1.0 1.0 Homoz.
14 0.96 1.0 Homoz. 1.0
15 Homoz. Homoz. 1.0 0.82
16 0.95 Homoz. 0.83 0.91
17 0.96 0.91 Homoz. Homoz.
18 Homoz. Homoz. Homoz. Homoz.
19 Homoz. 0.35 0.0 0.23
20 1.0 Homoz. 1.0 0.83
21 0.34 0.28 0.21 Homoz.
22 Homoz. 1.0 0.62 0.55
23 Homoz. 0.91 0.23 0.83
24 0.99 Homoz. Homoz. 0.91
25 1.0 0.83 Homoz. Homoz.
26 0.99 1.0 0.78 Homoz.
27 1.0 1.0 0.83 Homoz.
28 Homoz. 1.0 1.0 Homoz.
29 1.0 0.99 0.92 0.91
30 0.94 Homoz. 0.92 Homoz.
31 Homoz. 0.0 0.37 0.0
32 0.94 Homoz. 0.83 Homoz.
33 1.0 0.91 0.83 0.77
34 0.98 0.71 Homoz. Homoz.
35 0.94 0.83 0.91 0.97
36 Homoz. 1.0 0.68 Homoz.
37 0.97 1.0 Homoz. Homoz.
38 0.93 0.91 1.0 0.91
39 Homoz. 0.91 0.91 0.99
40 Homoz. 0.85 0.91 1.0
41 Homoz. Homoz. 1.0 Homoz.
42 Homoz. 0.91 0.91 Homoz.
43 0.45 Homoz. 0.86 1.0
44 1.0 0.91 0.83 1.0
Homoz. = homozygosity. Numbers in bold = Q (peak area) ≤ 0.50
indicating LOH.
presented LOH for IRF-1. Among the 3 patients with dele-
tion 7q or monosomy 7 (cases 19, 21, and 38), two cases
(19 and 21) presented LOH for at least one intragenic
microsatellite of 7q31.1. Only 1 patient (case 5) with nor-
mal karyotype by G-banding presented LOH. It was for the
marker D7S515. Otherwise, FISH centromeric probe for
chromosome 7 showed monosomy in 25% of the cells. The
2 patients with complex karyotype (cases 21 and 43)
presented LOH for IRF-1. The karyotype of case 21 was
47,XX,+8[1]/47,XX,del(5)(q13q33),del(7)(q22),+8[2]/
49,XX,del(7)(q22),+8,+11,+18[1] and case 43 was 53-
56,XX,+1,+8,+9,+10,i?(11)(q13),+14,+15,+16,+17,+18,
+19,~6dmin.
It is important to note that there was a significantly
positive association of the occurrence of LOH with abnor-
mal karyotype (P < 0.05; chi-square test).
LOH on chromosome 7q has been frequently reported
in several types of human cancer including myeloid neo-
plasia (1). Using a panel of three microsatellite markers at
band 7q31, we found 5 of 44 (11%) patients with one or
more allelic loss. Among these 5 cases, three presented
cytogenetic abnormalities involving chromosome 7 (cases
5, 19, and 21). Case 5 presented monosomy 7 by FISH and
LOH for D7S515; case 19 showed monosomy 7 and LOH
of the three markers, as expected; case 21 presented LOH
of D7S486 and D7S515, but the deletion was at band
7q22. Koike et al. (11) studied the LOH on the long arm of
chromosome 7 in AML patients using a panel of 15 mark-
ers and found a higher incidence of LOH (27%) than in the
present study probably due to the different panel with more
markers (fifteen). In fact, Basirico et al. (12) studied the
LOH of 7q using a panel of 11 polymorphic microsatellite
markers at band 7q21-36 and correlated the findings with
conventional karyotype. Sixteen patients (16/50) showed
allelic loss, but only three presented cytogenetic abnor-
malities related to chromosome 7. Our results suggest that
LOH in different microsatellite markers on the long arm of
chromosome 7 is an event previous to chromosomal ab-
normalities in these myeloid neoplasias, with karyotype
abnormalities occurring later.
An important finding among the present cases was the
correlation between LOH of IRF-1 and complex karyotype
with a lot of trisomies, deletions, isochromosome and
double minutes concomitantly. An interesting aspect that
remains to be determined is if IRF-1 gene expression is
decreased in these cases of LOH. Unfortunately, immuno-
histochemistry for IRF-1 performed in these cases was not
successful, and there were no more samples available for
additional molecular studies. Notwithstanding, IRF-1 has
been implicated as a mediator for interferon signaling, when
induced by TNF-α, interferons, viral infections and retinoids.
IRF-1 has been considered to be a TSG that plays an
essential role in cell growth control and surveillance against
malignant development (13). The findings of the present
study support the view of IRF-1 as an important TSG.
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